top of page
11-chemical-peel-peeling-orgev-.jpg
Chemical peels

 

From the epidermal to the basal layer: A variety of superficial peels crafted to stimulate epidermal growth through gentle removal of the stratum corneum, individually adapted to address each patient's specific needs.

PROFESSIONAL

A professional range:

ORGEV Laboratories® manufactures a professional range of safe, effective and easy-to-use chemical peels formulated to treat signs of helioderma (photoaging), hyperpigmentation and acne. ORGEV® chemical peels are professional products manufactured under strict quality control and according to the latest international standards.

Revipeel-70-Orgev.jpg
Revipeel® 70 - Skin rejuvenation

Superficial chemical peel that corrects and significantly reduces the visible signs of aging. It improves the cutaneous condition and gives the skin a more youthful appearance. Recommended for patients with: Fine lines and wrinkles, slackening skin, skin imperfections, dull and irregular complexions. ACTIVE INGREDIENT: Glycolic acid (70%). PACKAGING: 6 x 8 mL vials | pH 1.2

Revipeel® 55 - Acne-prone skin

Superficial peel indicated for the treatment of severe acne. ACTIVE INGREDIENTS: Glycolic acid, Salicylic acid, Lactic acid. PACKAGING: 6 x 8 mL vials | pH 1.4

orgev-revipeel-55.jpg
orgev-revipeel-50_edited.jpg
Revipeel® 50 - Skin Lightening

Lightening peel indicated for the correction of superficial melasma, post-inflammatory pigmentation, uneven complexion, and lentigines caused by the sun. A double action will remove intra-epidermal melanin residues by desquamation and reduce dermal-epidermal melanin synthesis by tyrosinase inhibition. ACTIVE INGREDIENTS: Glycolic acid, Phytic acid, Mandelic acid. PACKAGING: 6 x 8 mL vials | pH 1.6

Pre- & post-peel care

To obtain the best results, adequate skin preparation and post-treatment procedures are essential. ORGéV® Laboratories provides products specifically designed to prepare, improve, and extend the actions of the peel solution.

Learn more.

For additional information and access to clinical studies, consult the brochure:

bottom of page